Ozempic, Wegovy & Mounjouro MDL Lawsuit: Latest Updates
Multidistrict litigation (MDL No. 3094) involving GLP-1 receptor agonist medications, such as Ozempic, Wegovy, and Mounjaro, is actively moving forward in the Eastern District of Pennsylvania. Plaintiffs allege that the manufacturers failed to warn users about serious health risks, including gastroparesis, intestinal blockages, and vision loss.
Read More
PFAS Lawsuit 2025 Update: What You Should Know
The PFAS multidistrict litigation (MDL No. 2873) is moving forward in the District of South Carolina, where over 10,000 cases remain active against major manufacturers like 3M, DuPont, and BASF. While 3M reached a $10 billion settlement in 2023 to resolve water utility claims, no global settlement has been reached for individual personal injury lawsuits.
Read More
Paraquat MDL Updates 2025: Latest Lawsuit News & Legal Developments
The herbicide, Paraquat, continues to be at the center of a national lawsuit alleging that long-term exposure can lead to Parkinson’s disease. The plaintiffs claim that the manufacturers of Paraquat failed to adequately warn consumers of the long-term risks.
Read More
Fosamax MDL Update 2025: Legal Developments and Case Status
Fosamax (alendronate), a widely used osteoporosis drug, remains the subject of multidistrict litigation (MDL) over allegations that it can cause serious bone injuries, including atypical femur fractures and osteonecrosis of the jaw (ONJ). Plaintiffs claim Merck failed to warn users adequately about these risks.
Read More
Paragard MDL Updates: What You Should Know
The Paragard IUD remains the subject of a major nationwide lawsuit, with claims alleging the device breaks during removal, leading to serious injuries that the manufacturers, Teva Pharmaceuticals, allegedly failed to adequately warn consumers about. These cases have been centralized in Multidistrict Litigation (MDL) No. 2974, in the Northern District of Georgia.
Read More
Understanding the Pre-Litigation Process: What to Do After a Car Accident
The time period immediately following a car accident is crucial not only for your health, but for protecting your legal rights. Prior to any lawsuits being filed, you enter the pre-litigation phase during which critical steps must be taken. Knowing what to do after an accident can make a major difference in the outcome of your personal injury claim and help preserve your right to compensation.
Read More
The Car Accident Negotiation Phase
The negotiation phase after a car accident is often the toughest part of resolving your claim. Insurance companies are skilled at minimizing payouts and may challenge the seriousness of your injuries, the necessity of your medical treatment, or the legitimacy of your lost wages. Getting through this process requires more than patience, it demands strong documentation and experienced legal representation.
Read More
Understanding Settlements After Motor Vehicle Accidents: How to Get the Compensation You Deserve
Most car accident cases settle before reaching court. A car accident settlement is an agreement where you and the insurance company, usually through your attorney’s negotiation, decide on a fair amount to compensate your injuries, medical bills, lost wages, and other damages.
Read More
What to Expect During Car Accident Litigation: How a Lawyer Guides You Through the Process
If your car accident claim can’t be resolved through negotiation or insurance settlement, it may enter litigation, a formal legal process where your case is handled in court. Although litigation after a car accident can feel overwhelming, having an experienced personal injury lawyer by your side can make all the difference.
Read More
Florida Tort Reform: Bad Faith Insurance Claims
“Bad faith” claims are pursued against insurers who act negligently. If your insurance company unfairly settled your account or didn’t pay enough money for your claim, you could sue the company for acting in bad faith. Updates to Florida’s tort law have provided new guidelines on how victims can file and pursue bad faith insurance lawsuits.
Read More